Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

Molecular Oncology

Volumn 9, Issue 3, 2015, Pages 569-585

  Abdel Fatah, Tarek M A ^a   Middleton, Fiona K ^b   Arora, Arvind ^c   Agarwal, Devika ^d   Chen, Tao ^b   Moseley, Paul M ^a   Perry, Christina ^c   Doherty, Rachel ^c   Chan, Stephen ^a   Green, Andrew R ^c   Rakha, Emad ^c   Ball, Graham ^d   Ellis, Ian O ^c   Curtin, Nicola J ^b   Madhusudan, Srinivasan ^a,c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

ATR; Biomarker; Breast cancer; CHEK1

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ATR PROTEIN; CHECKPOINT KINASE 1; CYCLOPHOSPHAMIDE; DNA; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; MESSENGER RNA; METHOTREXATE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VE 821; ATM PROTEIN; ATR PROTEIN, HUMAN; PHOSPHOSERINE; PROTEIN KINASE;

ADJUVANT THERAPY; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM CELL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA REPLICATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; INVASIVE CARCINOMA; LC50; LYMPH VESSEL METASTASIS; MCF 7 CELL LINE; MITOSIS INDEX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; VALIDATION PROCESS; BREAST NEOPLASMS; CELL PROLIFERATION; COHORT ANALYSIS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGICAL STRESS; PROGNOSIS; REPRODUCIBILITY; TUMOR CELL LINE; TUMOR INVASION;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHORYLATION; PHOSPHOSERINE; PROGNOSIS; PROTEIN KINASES; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; STRESS, PHYSIOLOGICAL;

EID: 84923357784     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.10.013     Document Type: Article

References (34)

1. Abdel-Fatah T.M., Albarakati N., Bowell L., Agarwal D., Moseley P., Hawkes C., Ball G., Chan S., Ellis I.O., Madhusudan S. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res. Treat. 2013, 142:515-527.
2. Abdel-Fatah T.M., Perry C., Dickinson P., Ball G., Moseley P., Madhusudan S., Ellis I.O., Chan S.Y. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann. Oncol. 2013, 24:2801-2807.
3. Abdel-Fatah T.M., Perry C., Moseley P., Johnson K., Arora A., Chan S., Ellis I.O., Madhusudan S. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res. Treat. 2014, 143:411-421.
4. Abdel-Fatah T.M., Russell R., Agarwal D., Moseley P., Abayomi M.A., Perry C., Albarakati N., Ball G., Chan S., Caldas C., Ellis I.O., Madhusudan S. DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol. Oncol. 2014, 8:520-532.
5. Abdel-Fatah T.M., Russell R., Albarakati N., Maloney D.J., Dorjsuren D., Rueda O.M., Moseley P., Mohan V., Sun H., Abbotts R., Mukherjee A., Agarwal D., Illuzzi J.L., Jadhav A., Simeonov A., Ball G., Chan S., Caldas C., Ellis I.O., Wilson D.M., Madhusudan S. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Mol. Oncol. 2014, 8:1326-1338.
6. Alderton G.K., Joenje H., Varon R., Borglum A.D., Jeggo P.A., O'Driscoll M. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum. Mol. Genet. 2004, 13:3127-3138.
7. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
8. Carrassa L., Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011, 10:2121-2128.
9. Charrier J.D., Durrant S.J., Golec J.M., Kay D.P., Knegtel R.M., MacCormick S., Mortimore M., O'Donnell M.E., Pinder J.L., Reaper P.M., Rutherford A.P., Wang P.S., Young S.C., Pollard J.R. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J.Med. Chem. 2011, 54:2320-2330.
10. Chen T., Stephens P.A., Middleton F.K., Curtin N.J. Targeting the S and G2 checkpoint to treat cancer. Drug Discov. Today 2012, 17:194-202.
11. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Graf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerod A., Green A., Provenzano E., Wishart G., Pinder S., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Borresen-Dale A.L., Brenton J.D., Tavare S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
12. Derheimer F.A., O'Hagan H.M., Krueger H.M., Hanasoge S., Paulsen M.T., Ljungman M. RPA and ATR link transcriptional stress to p53. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12778-12783.
13. Flynn R.L., Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem. Sci. 2011, 36:133-140.
14. Fokas E., Prevo R., Hammond E.M., Brunner T.B., McKenna W.G., Muschel R.J. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2014, 40:109-117.
15. Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J. Hypoxia links ATR and p53 through replication arrest. Mol. Cell Biol. 2002, 22:1834-1843.
16. Lin W.Y., Brock I.W., Connley D., Cramp H., Tucker R., Slate J., Reed M.W., Balasubramanian S.P., Cannon-Albright L.A., Camp N.J., Cox A. Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer. PLoS One 2013, 8:e68578.
17. Marechal A., Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 2013, 5.
18. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J.Natl. Cancer Inst. 2005, 97:1180-1184.
19. Merry C., Fu K., Wang J., Yeh I.J., Zhang Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010, 9:279-283.
20. Meuth M. Chk1 suppressed cell death. Cell Div. 2010, 5:21.
21. Nam E.A., Cortez D. ATR signalling: more than meeting at the fork. Biochem. J. 2011, 436:527-536.
22. Niida H., Katsuno Y., Banerjee B., Hande M.P., Nakanishi M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol. Cell Biol. 2007, 27:2572-2581.
23. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., Mansukhani M., Murty V.V., Gaciong Z., Meek S.E., Piwnica-Worms H., Hibshoosh H., Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204.
24. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., Golec J.M., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
25. Reinhardt H.C., Hasskamp P., Schmedding I., Morandell S., van Vugt M.A., Wang X., Linding R., Ong S.E., Weaver D., Carr S.A., Yaffe M.B. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol. Cell 2010, 40:34-49.
26. Reinhardt H.C., Yaffe M.B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol. 2009, 21:245-255.
27. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108:73-112.
28. Sorensen C.S., Syljuasen R.G. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012, 40:477-486.
29. Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N., Seedhouse C., Ball G., Chan S., Rakha E.A., Ellis I.O., Madhusudan S. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013, 73:1621-1634.
30. Verlinden L., Vanden Bempt I., Eelen G., Drijkoningen M., Verlinden I., Marchal K., De Wolf-Peeters C., Christiaens M.R., Michiels L., Bouillon R., Verstuyf A. The E2F-regulated geneChk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res. 2007, 67:6574-6581.
31. Wang J., Han X., Feng X., Wang Z., Zhang Y. Coupling cellular localization and function of checkpoint kinase 1 (Chk1) in checkpoints and cell viability. J.Biol. Chem. 2012, 287:25501-25509.
32. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J.Clin. Oncol. 2013, 31:3997-4013.
33. Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S., Zhang H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J.Biol. Chem. 2003, 278:21767-21773.
34. Zhang Y., Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int. J. Cancer 2014, 134:1013-1023.